Engineered charge adaptive nanoplatform overcomes the drug penetration barriers to potentiate the efficacy of chemotherapy.

ABSTRACT: Breast cancer continues to present a major clinical hurdle, largely attributable to its aggressive metastatic behavior and the suboptimal efficacy of standard chemotherapeutic regimens. Cisplatin (CDDP) is a representative platinum drug in the treatment of breast cancer, however, its therapeutic application is often constrained by systemic toxicity and the frequent onset of chemoresistance. Here, we introduce a novel charge-adaptive nanoprodrug system, referred to as PP@, engineered to respond to tumor-specific conditions. This platform was constructed by conjugating ibuprofen and polyethylene glycol (PEG) to the hydrophobic and hydrophilic termini of an amphiphilic dendrimer, respectively, enabling the formation of uniform and stable nanostructures through spontaneous self-assembly. Impor

SUBMITTER: Xie G 

PROVIDER: S-EPMC12414913 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature